Open AccessRare DNA Mismatch Repair-Related Protein Loss in Patients with Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma and Their Response to Immunotherapy
Author(s) -
Jing Yu,
Xi Zhang,
Qiyue Huang,
Sirui Tan,
Xianze Xiong,
Hongfeng Gou
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s304281
Subject(s) - medicine , msh2 , msh6 , intrahepatic cholangiocarcinoma , pms2 , mlh1 , oncology , response evaluation criteria in solid tumors , dna mismatch repair , gastroenterology , cancer , chemotherapy , progressive disease , colorectal cancer
The patients with advanced mismatch repair deficiency (dMMR) cancers can benefit from programmed cell death 1 (PD-1) pathway blockade, regardless of the tumor type. Little is known about the prevalence of dMMR in intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular-cholangiocarcinoma (cHCC-CC). This study aimed to assess the mismatch repair (MMR)-related protein expression in patients with ICC and cHCC-CC.